JOHNSON & JOHNSON
JNJNYSEDrug Manufacturers - General • Healthcare
Comprehensive AI Analysis
Strategic AI Analysis for JNJ
Checking whether the approved providers contain enough current financial data for a reliable report.
Summary
Source-linked company research for JNJ
Factor Scorecard
Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.
Latest results at a glance
Insights from the latest company results and reports · filed 15 Jul 2026
Q2 2026 Earnings Exceed Consensus
Reported adjusted EPS of $2.90 per share for the quarter ended June 2026 exceeded the same-quarter consensus estimate of $2.85 per share.
Quarterly Revenue Surpasses $25 Billion
Revenue for the quarter ended June 28, 2026, was $25.31 billion, representing a 6.60% increase from the prior-year period.
2026 Guidance Raised
The company increased 2026 adjusted EPS guidance by $0.13 to a midpoint of $11.68, and adjusted operational EPS guidance by $0.18 to a midpoint of $11.58.
Gross Margin Expansion
Gross margin for the quarter ended June 28, 2026, was 68.19%, wider than the 67.87% recorded in the same quarter of the prior year.
New FDA Approval for IMAAVY
Johnson & Johnson secured FDA approval for IMAAVY, the first targeted therapy for warm autoimmune hemolytic anemia in adults and youth.
Price Chart
NYSE:JNJ via TradingView
Loading TradingView chart...
Overview
Quarterly income statement data isn't available for this company.
No Data
No annual financial data available.
Financial Fundamentals
Growth, quality, valuation, cash generation, and balance-sheet strength.
Growth
TTM revenue plus current, long-term, forward, and accelerating top-line trends.
Earnings
Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.
Profitability
TTM margin and return metrics that reflect pricing power and business quality.
Cash Flow
TTM free cash flow, growth, margin, and operating-cash conversion quality.
Valuation
Metrics ranked by issuer type, financial state, and input quality.
Forward P/E
Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.
Financial Health
Latest-quarter liquidity and leverage checks plus TTM interest coverage.
Shareholder Signals
Capital returns and dilution checks sourced from statements and insider filings.
Peer Comparison
| Ticker | Price | Mkt Cap | EV/EBITDA | Fwd P/E | Rev Growth | Gross Margin | FCF Yield |
|---|---|---|---|---|---|---|---|
JNJJOHNSON & JOHNSON | $268.04 | $645.9B | 19.5x | 24.3x | +8.1% | 67.9% | 3.4% |
Company Profile
About the Company
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Next Earnings Date
Oct 13, 2026
Loading latest news...